Submitted by Anonymous (not verified) on 2 October 2025 - 15:05
Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 3, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 3, Status: Authorised